As with most other chronic diseases, such as diabetes, asthma, or heart disease, treatment for drug addiction generally isn’t a cure. However, addiction is treatable and can be successfully managed. People who are recovering from an addiction will be at risk for relapse for years and possibly for their whole lives. Research shows that combining addiction treatment medicines with behavioral therapy ensures the best chance of success for most patients. Treatment approaches tailored to each patient’s drug use patterns and any co-occurring medical, mental, and social problems can lead to continued recovery.
The hidden cost of alcoholism does not stop with health. Alcoholism is also linked to violent crime, resulting in a cost to the economy in terms of policing and prosecution. However, it is difficult to put a price on the impact that alcoholism has to society. A report by the IAS showed that a figure of £21 billion is regularly quoted by the Government in terms of the cost of alcohol to society (in England and Wales). This does not include the personal cost of alcoholism and only considers the cost that is imposed on others.
Dangerous behaviors common among alcoholics include impaired judgment and coordination, falling asleep at the wheel, falling asleep with lit cigarettes, aggressive outbursts, drinking to the point of vomiting, hangover, or alcohol poisoning — and these are just the ones most alcoholics experience in the course of their disease. All of these behaviors will eventually hit the system, in the form of health care costs, criminal justice costs, motor vehicle crash costs, and workplace productivity
When you have a child struggling with substance abuse, attempting to handle it on your own can be extremely overwhelming and can eventually become your first and only priority. It may also be difficult to take the first step because addressing the problem is disruptive of school and extracurricular activities.2 However, addiction is far more disruptive to your child's life in the end, and treatment can work. Taking the time now to get help can save your child's life.
A growing literature is demonstrating the importance of emotion regulation in the treatment of substance abuse. Considering that nicotine and other psychoactive substances such as cocaine activate similar psycho-pharmacological pathways, an emotion regulation approach may be applicable to a wide array of substance abuse. Proposed models of affect-driven tobacco use have focused on negative reinforcement as the primary driving force for addiction; according to such theories, tobacco is used because it helps one escape from the undesirable effects of nicotine withdrawal or other negative moods. Acceptance and commitment therapy (ACT), is showing evidence that it is effective in treating substance abuse, including the treatment of poly-substance abuse and cigarette smoking. Mindfulness programs that encourage patients to be aware of their own experiences in the present moment and of emotions that arise from thoughts, appear to prevent impulsive/compulsive responses. Research also indicates that mindfulness programs can reduce the consumption of substances such as alcohol, cocaine, amphetamines, marijuana, cigarettes and opiates.
Inpatient treatment is a good choice for anyone who wants to focus completely on recovery without the stress or distractions of work, school, or social obligations. It allows for a thorough immersion in the recovery process and may be a good choice for people who have tried other treatments unsuccessfully. Inpatient treatment for alcohol rehabilitation may last anywhere from 30 days to six months or longer — recovery times depend on the needs of the individual.
Nalmefene, an opiate antagonist that is similar in its chemical structure to naltrexone, is one of the most recent drugs being investigated for the treatment of alcoholism. Like naltrexone (sold as ReVia, Depade, or Vivitrol), nalmefene deprives the person struggling with substance use of the pleasurable feelings associated with drinking. But nalmefene is less toxic to the liver than naltrexone. As of 2013, nalmefene was still undergoing clinical trials through the U.S. National Institutes of Health before receiving FDA approval. From Rehab to a Body Bag | Dying for Treatment: VICE Reports (Full Length)